Recursion Pharmaceuticals (RXRX) director trades 40,000 shares in plan sale
Rhea-AI Filing Summary
Recursion Pharmaceuticals director Christopher Gibson reported converting 40,000 shares of Class B Common Stock into Class A Common Stock on June 5, 2026, and selling 40,000 Class A shares at $3.6200 per share in a transaction reported as pursuant to a Rule 10b5-1 trading plan adopted May 12, 2025. After these trades, he reported holding 883,735 shares of Class A Common Stock directly.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 40,000 shares ($145K approx. pre-tax spread)
Exercise and Sale
12 txns
Insider
Gibson Christopher
Role
Director
Sold
40,000 shs ($145K)
Approx. gross sale proceeds
$145K
Approx. exercise cost
$0.00
Approx. pre-tax spread
$145K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Class B Common Stock | 40,000 | $0.00 | $0.00 |
| Conversion | Class A Common Stock | 40,000 | $0.00 | $0.00 |
| Sale | Class A Common Stock | 40,000 | $3.62 | $145K |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Class B Common Stock — 4,263,334 shares (Direct);
Class A Common Stock — 883,735 shares (Direct);
Class B Common Stock — 0 shares (Indirect, by LAHWRAN-3 LLC);
Class B Common Stock — 0 shares (Indirect, by LAHWRAN-4 LLC);
Class B Common Stock — 0 shares (Indirect, by Gibson Family Trust);
Stock Option (Right to Buy) — 0 shares (Direct)
Footnotes (11)
- F1. Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a sale of the shares by the Reporting Person. Each share of Class B Common Stock is convertible into one share of Class A Common Stock.
- F2. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025.
- F3. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
- F4. The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
- F5. The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
- F6. The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.
- F7. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- F8. The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- F9. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- F10. The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- F11. The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Key Figures
Shares converted: 40,000 shares
Shares sold: 40,000 shares
Sale price: $3.6200 per share
+2 more
5 metrics
Shares converted
40,000 shares
Class B to Class A conversion on June 5, 2026
Shares sold
40,000 shares
Class A Common Stock sale on June 5, 2026
Sale price
$3.6200 per share
Price for the 40,000-share Class A sale
Post-transaction Class A holding
883,735 shares
Class A Common Stock held directly after June 5, 2026 trades
Rule 10b5-1 plan adoption date
May 12, 2025
Trading plan referenced for the reported transactions
Key Terms
Rule 10b5-1 trading plan, Class B Common Stock, Stock Option (Right to Buy), conversion of derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This transaction is pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Class B Common Stock financial
"automatic conversion of Class B Common Stock into Class A"
A class B common stock is one of multiple types of a company’s ordinary shares that carries specific rights—often different voting power or dividend priority—compared with other classes. For investors it matters because those differences affect how much influence you have over company decisions, the income you might receive, and how freely the shares trade; think of it like owning a car with different keys: some keys let you start the engine and open the trunk, others only unlock the door.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with specified exercise prices"
conversion of derivative security financial
"transaction code description: Conversion of derivative security"
underlying security financial
"underlying security title: Class A Common Stock"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did RXRX director Christopher Gibson report?
Christopher Gibson reported a conversion and sale of Recursion Pharmaceuticals (RXRX) shares. He converted 40,000 Class B shares into Class A and sold 40,000 Class A shares on June 5, 2026, under a Rule 10b5-1 trading plan.
Was Christopher Gibson’s RXRX stock sale under a Rule 10b5-1 plan?
Yes. The filing states the transactions were made under a Rule 10b5-1 trading plan adopted on May 12, 2025. Such plans allow pre-arranged trading, which can reduce the informational significance of trade timing for Recursion Pharmaceuticals (RXRX).
Did Christopher Gibson exercise options or only sell RXRX stock?
The Form 4 reports a conversion of derivative security, where 40,000 Class B shares converted into Class A, followed by a sale of 40,000 Class A shares. It also lists multiple stock option holdings with various exercise prices and future expiration dates.